New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis

• Autor(a) principal: Silva, DR
• Data de Publicação: 2018
• Outros Autores: Dalcolmo, M, Tiberi, S, Arbex, MA, Munoz-Torrico, M, Duarte, R, D'Ambrosio, L, Visca, D, Rendon, A, Gaga, M, Zumla, A, Migliori, GB
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/10216/154217
• topic: Tuberculosis/therapy; Tuberculosis; multidrug-resistant; Extensively drug-resistant tuberculosis; Antitubercular agents

Multidrug-resistant and extensively drug-resistant tuberculosis (MDR-TB and XDR-TB, respectively) continue to represent a challenge for clinicians and public health authorities. Unfortunately, although there have been encouraging reports of higher success rates, the overall rate of favorable outcomes of M/XDR-TB treatment is only 54%, or much lower when the spectrum of drug resistance is beyond that of XDR-TB. Treating M/XDR-TB continues to be a difficult task, because of the high incidence of adverse events, the long duration of treatment, the high cost of the regimens used, and the drain on health care resources. Various trials and studies have recently been undertaken (some already published and others ongoing), all aimed at improving outcomes of M/XDR-TB treatment by changing the overall approach, shortening treatment duration, and developing a universal regimen. The objective of this review was to summarize what has been achieved to date, as far as new and repurposed drugs are concerned, with a special focus on delamanid, bedaquiline, pretomanid, clofazimine, carbapenems, and linezolid. After more than 40 years of neglect, greater attention has recently been paid to the need for new drugs to fight the white plague, and promising results are being reported.